Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06788275
Recruiting Not applicable

Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease

NCT06788275 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2024-11-01
Last updated
2026-02-27

Condition(s) studied

Percutaneous Coronary Intervention (PCI)Acute Myocardial InfarctionAngina (Stable)Unstable Angina PectorisCardiorespiratory FitnessIschaemic Heart Diseases

Investigational drug(s) / intervention(s)

Aerobic exercise (MIT)Aerobic exercise (Short HIIT)Aerobic exercise (Long HIIT)

Aerobic exercise (MIT): Patients allocated to the MIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Aerobic exercise (Short HIIT): Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Aerobic exercise (Long HIIT): Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.

Study summary

Endothelial dysfunction is one of the aetiological factors in ischaemic heart disease (IHD). Aerobic exercise is effective in improving endothelial function, as measured by flow-mediated dilation (FMD), in patients with IHD. Within the aerobic exercise methods, there is evidence showing that high-intensity interval training (HIIT) increases FMD to a greater extent than moderate-intensity training (MIT) in these patients. Notably, in a recent review, our research group found that only studies performing long bouts of HIIT (long HIIT: higher than 1 min) found a greater effect on FMD, while no differences were found in those studies using short bouts of HIIT (short HIIT: ≤ 1 min) and MIT. However, no experimental studies comparing the effect of long HIIT, short HIIT, and MIT on endothelial function, as well as other predictors of mortality, such as cardiorespiratory fitness, brain-derived neurotrophic factor (BDNF) levels or parasympathetic branch activity, have been performed. Therefore, the main objective of this project will be to compare the effect of the three aerobic exercise methods on endothelial function, as measured by FMD, in patients with IHD. Complementarily, the effect of aerobic exercise, depending on the exercise method, on different mortality predictors will be compared. For this purpose, a multicentre randomised study will be carried out (2 hospitals in Elche and one in Alicante). Assessors will be blinded to the patients allocation. Participants will be aware about their allocation in the experimental groups due to the nature of the study. A total of 132 men and women with IHD (66 per sex), diagnosed between three and 12 months before the start of the intervention, aged between 45 and 75 years, and without limitations for the practice of exercise training, will be recruited. All patients will train 3 days a week for 12 weeks. Participants will be assessed before the intervention (i.e., pre), at 6 weeks of training (i.e., mid) and after the intervention (i.e., post). Physiological and psychological variables will be registered in the assessment periods. Training intensity will be individually prescribed based on the cardiopulmonary exercise test (CPET). Intensity exercise will be adapted after the first part of the intervention. Analysis of covariance will be used to compare the values of the three groups after the intervention for the continuous variables, including the pre-intervention value as a covariate, while a logistic regression model will be used for the categorical variables.

Eligibility

Sex
ALL
Min age
45 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Men and women aged between 45 and 75 years. * Diagnosed with acute myocardial infarction, unstable or stable angina. * Treated with percutaneous coronary intervention, coronary artery bypass grafting, or conservative treatment. * Event or intervention within 3 to 12 months prior to participation in the study. * Fluency in speaking and reading Spanish. * Residing in Elche or surrounding areas and able to attend evaluations and the exercise programme (not planning to be absent for more than one week during the programme). * Functional Class I-II according to the New York Heart Association (NYHA) classification. * No physical limitations for exercise. * Stable optimal medical treatment. * Physically inactive, defined as 1) not meeting the World Health Organization recommendations for both aerobic and strength exercise, and 2) not participating in a structured exercise programme at least 3 days per week for more than 3 months. Both conditions must be met for inclusion. Note: Casual walking is not considered grounds for exclusion. Exclusion Criteria: * Use of walking assistive devices. * Treatment with chemotherapy for any type of cancer in the past 2 years. * Hospitalisation in an intensive care unit in the past 6 months for reasons other than the ischaemic event. * Acute myocardial infarction group IV Killip-Kimball. * Obesity grade III (≥40.0 kg/m²). * Medical contraindication for inclusion in an exercise programme. * Diabetes with uncontrolled blood glucose levels. * Poorly controlled hypertension: resting blood pressure \> 180/110 mmHg. * Chest pain with exertion or ST-segment changes suggestive of residual ischemia during ergometry. Residual ischemia. * Severely reduced functional capacity on initial ergometry (\<5 metabolic equivalent of task). * Left ventricular ejection fraction less than 50%. * Severe stenosis of the left main coronary artery (\>50% significant disease). * Severe aortic stenosis, left ventricular outflow tract obstruction (e.g., obstructive hypertrophic cardiomyopathy) or aortic dissection. * Severe valvulopathy. * Acute pulmonary embolism or deep vein thrombosis. * Severe pulmonary hypertension. * Acute heart failure. * Acute endocarditis, myocarditis, or pericarditis. * Acute or chronic renal insufficiency (estimated glomerular filtration rate \<30 ml/min). * Pulmonary fibrosis or interstitial disease (severe respiratory insufficiency or confirmed chronic obstructive pulmonary disease). * Uncontrolled cardiac arrhythmias/hemodynamically unstable. * Permanent or persistent/paroxysmal atrial fibrillation with episodes in the past 6 months. * High-grade cardiac block. * Presence of implantable devices: cardiac resynchronization therapy pacemaker, implantable cardioverter defibrillators, or pacemaker. * Presence of ischaemic symptoms during the incremental exercise test performed before the intervention. * Severe autonomic or peripheral neuropathy. * Use of nitrates in pharmacological treatment. * Any planned surgical or medical intervention during the study period. * Plans to participate in or current participation in other studies that may interfere with this study. * Current pregnancy or intention to become pregnant during the study period.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Instituto de Investigación Sanitaria y Biomédica de Alicante Alicante Alicante Recruiting
Centro de Investigación del deporte Elche Alicante Recruiting

More Instituto de Investigación Sanitaria y Biomédica de Alicante trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06788275 on ClinicalTrials.gov ↗ ← All trials in Spain